Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Psoriatic Arthritis

An Introduction to Psoriatic Arthritis

Psoriatic arthritis is a chronic, progressive, inflammatory form of arthritis, which develops in up to 30% of people with psoriasis and is associated with increased risk of systemic inflammatory disease. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, disease-modifying antirheumatic drugs (DMARDs) and biologic therapies, including inhibitors of tumour necrosis factor (TNF) α, interleukin (IL)-12, IL-23 and IL-17. Recently approved therapies include the Janus kinase (JAK) inhibitors, and other promising agents in development include tyrosine kinase inhibitors. Future challenges include personalised medicine, earlier diagnosis and achieving a low-level of disease activity.

Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.

Our supporting partners do not constitute an endorsement of the content on this page.

Coverage from: EULAR Highlights

The Phase II ARGO trial evaluated the IL-17A and IL-17F inhibitor sonelokimab in psoriatic arthritis, showing promising clinical efficacy and significant improvements in patient-reported outcomes (PROs). In this interview, Prof. Laure Gossec highlights how sonelokimab reduced disease burden and improved quality of life, emphasizing the importance of PROs in assessing treatment effectiveness and guiding future development.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

In this edition of our Future Leaders series, we speak with Dr. Santhanam Sham, a rising star in rheumatology. As a Senior Consultant at Kauvery Hospitals, Chennai, Dr. Sham is dedicated to advancing research on autoimmune diseases like SLE and vasculitis, while also fostering patient-centric care and embracing cutting-edge medical technologies.

Mark CompleteCompleted
BookmarkBookmarked

To gain expert insight into the most impactful developments of the past year and the trends set to shape the next, we reached out to our esteemed expert faculty. From advances in targeted therapies to the integration of AI and steps towards precision medicine, here’s what our experts had to say.

Mark CompleteCompleted
BookmarkBookmarked

On September 23, 2024, the U.S. Food and Drug Administration (FDA) approved bimekizumab-bkzx (BIMZELX®, UCB) for the treatment of active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and active ankylosing spondylitis (AS).1 This makes bimekizumab-bkzx ...

Mark CompleteCompleted
BookmarkBookmarked

As we have come to expect, EULAR 2024 was a busy and productive meeting, packed with news and lively discussions among rheumatologists. The conference, which took place in Vienna, Austria, highlighted a wealth of innovative research and significant advancements in rheumatology. ...

Developed by Touch
Coverage from: EULAR 2024

To understand what sets izokibep apart from other IL-17 inhibitors and its potential for treating PsA, we spoke with one of the study's investigators, Prof. Peter Taylor. Prof. Taylor discusses the study's findings, focusing on its efficacy and tolerability, and explores what these results could mean for clinical practice. With several IL-17 inhibitors already approved or in development for PsA, we also examine how izokibep could fit into the current treatment paradigm. Additionally, we discuss the importance of ongoing research to fully determine izokibep's benefit/risk ratio and optimal dosage

Mark CompleteCompleted
BookmarkBookmarked

Psoriatic arthritis (PsA) is a typical complication of psoriasis (PSO) that is often accompanied by nail PSO, vertebral and/or pelvic involvement, enthesitis and iritis. PsA leads to the destruction and/or ankylosis of the peripheral joints or spine, resulting ...

Developed by Touch
Coverage from: ACR Highlights

In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial ...

Developed by Touch
Coverage from: ACR Highlights

The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing ...

Developed by Touch
Coverage from: EULAR Highlights

The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital ...

Developed by Touch
Coverage from: EULAR Highlights

Upadacitinib is an oral JAK1 inhibitor approved for the treatment of psoriatic arthritis. It was a pleasure to talk with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) about the impact of axial involvement on patients with psoriatic arthritis ...

Mark CompleteCompleted
BookmarkBookmarked

Psoriatic arthritis (PsA) is a chronic inflammatory disease with an estimated global prevalence of 0.2%.1,2 The condition may occur in up to 30% of patients with psoriasis, with PsA typically developing 10 years after the onset of skin disease.1,3,4 PsA is a highly ...

Coverage from: ACR Highlights

We were delighted to speak with Dr. Michaela Koehm (Goethe University, Frankfurt am Main, Germany) to discuss her trial investigating the effect of methotrexate on ustekinumab treatment for active psoriatic arthritis. This information is brought to you by Touch Medical ...

Coverage from: ACR Highlights

It was a pleasure to discuss with Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) the results from the further exploratory analysis of the phase 2 trial (NCT03881059) investigating the TYK2 inhibitor, deucravacitinib, in patients with psoriatic arthritis ...

Coverage from: ACR Highlights

Prof. Merav Lidar (Sheba Medical Center, Tel Hashomer, Israel) kindly took the time to discuss the 24-week efficacy and safety results from the KEEPsaKE2 trial (NCT03671148). This phase 3 randomized, double-blind trial investigated the humanized immunoglobulin G1 monoclonal antibody, risankizumab, in ...

Load More...
Close Popup